References
- Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85(6 Pt 2): 521–44
- Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105(4): 664–72
- Kaplan AP. Urticaria and angioedema. In: Middleton E Jr, Reed CE, Ellis EF, et al, eds. Allergy: principles & practice. 6th ed, vol 2. St Louis: Mosby- Year Book, 2002: 1537–58
- Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114(3): 465–74; quiz 475
- Mastalerz L, Setkowicz M, Sanak M, et al. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113(4): 771–5
- Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28(2): 123–7
- Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclooxy- genase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89(1): 63–6
- Zembowicz A, Mastalerz L, Setkowicz M, et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003; 139(12): 1577–82
- Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8–13
- Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164(8): 910–3
- Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346(3): 175–9
- Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FcεRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002; 110(3): 492–9
- Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107(6): 1056–62
- Sheikh J. Advances in the treatment of chronic urticaria. Immunol Allergy Clin North Am 2004; 24(2): 317–34, vii–viii
- Rumbyrt JS, Schocket AL. Chronic urticaria and thyroid disease. Immunol Allergy Clin North Am 2004; 24(2): 215–23, vi
- Abdi R, Dong VM, Lee CJ, et al. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy 2002; 22(9): 1173–5
- Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32(1): 133–9
- Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113(1): 134–40
- Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110(3): 484–8
- Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32(12): 1763–8
- Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: a role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4(5): 297–305